Posts Tagged ‘cancer’

Sculpted to a T: Synthetic T-cells for a more controlled immune response

Author: Holly Wobma, 10/18/16

I have a confession.  This is not a blog about stem cells. It is, however, a blog about cells with infinite possibilities of fate. Because we are entering the world of synthetic biology, where crafty cellular engineering has enabled a new level of control over immune cell function. This work comes out of Wendell Lim’s…Read more

ISSCR final day – Not just one hit… finding combinations in cancer

Author: David Kent, 07/18/16

During the morning plenary session on the final day of ISSCR, we were treated to a delightful mix of basic and translational science as well as a riveting public policy lecture from Alta Charo. The session was all about disease modeling and stem cells and the highlight talk for me was from Guy Sauvageau, who…Read more

Cell Therapy Deal Review: March

Author: Mark Curtis, 04/25/16

Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma. Cellectis (CLLS) has already separated itself from the pack with UCART19, a universal CAR product targeting…Read more

Update from the Clinic: January

Author: Mark Curtis, 02/22/16

Welcome to your update from the clinic for the month of January. It was a quiet month in the clinic. However, we did see some clearances for various clinical studies, including Fate’s ProTmune in GvHD and Pluristem’s PLX-R18 in hematopoietic recovery following bone marrow transplant. Pluristem (PSTM) continues to increase the breadth of applications for…Read more

Cell Therapy Deal Review: January

Author: Mark Curtis, 02/18/16

Welcome to your Cell Therapy Deal Review for the month of January. Things got off to a quick start with a number of cell-based immunotherapy companies announcing deals and research collaborations out of the gate, including a third acquisition by Juno. Juno Therapeutics (JUNO) brought further depth to its research & discovery platform through the…Read more

Right Turn: An estimated 22,465 people died from cancer yesterday

Author: Stacey Johnson, 02/05/16

According to the World Health Organization, there were 8.2 million cancer related deaths in 2012 so by my calculations, that’s over 22,000 each day. Cancer has been on my mind a lot this week, and not just because yesterday was #WorldCancerDay. On February 1st, the wife of a friend passed away from leukaemia. She had…Read more

Stem cell community loses a treasured friend

Author: Guest, 01/18/16

Joe Sornberger is Director of Communications Programs for the Canadian Stem Cell Foundation and author of Dreams & Due Diligence: Till and McCulloch’s Stem Cell Discovery and Legacy. This post is published here with his permission. The stem cell community is mourning the loss of one of its most cherished champions, Andrew David Lyall. Mr. Lyall…Read more

Right Turn: Cancer campaigns

Author: Stacey Johnson, 11/27/15

To some people, November is now Movember. That is testament to how successful and pervasive this campaign for men’s health – especially prostate cancer – has become. (Blogger Sara Nolte has also chosen to write about prostate cancer during Movember.) Last month the focus was on breast cancer. The month before that, there were a…Read more

Cell Therapy Deal Review: October

Author: Mark Curtis, 11/24/15

Welcome to your Cell Therapy Deal Review for the month of October. Lion Biotechnologies and Kite Pharma both made deals with the National Institutes of Health (NIH) that significantly expanded their respective pipelines. Kite also announced a research collaboration with Alpine Immune Sciences to enhance its CAR T portfolio with a novel transmembrane protein platform….Read more

Update from the Clinic: September

Author: Mark Curtis, 10/27/15

Welcome to your Update from the Clinic for the month of September. OncoSec Medical released some initial data from its Phase 1/2 study investigating ImmunoPulse IL-12 DNA in a rare skin cancer. Pluristem and the National Institute of Allergy and Infectious Diseases (NIAID) have agreed upon a trial design for Pluristem’s Phase 2 study investigating…Read more